OBJECTIVES: We sought to determine whether serum citrulline (CIT), an amino acid produced by small bowel enterocytes, was associated with clinical and biochemical markers of gastrointestinal function in children undergoing hematopoietic cell transplantation (HCT). METHODS: We conducted a multicenter, prospective cohort study of 26 children to define time-related changes in serum CIT during the course of HCT. Markers of gastrointestinal function including oral energy intake, emesis, stool volume, presence of graft-versus-host disease (GVHD), oral mucositis severity, and cytokine and neurohormone levels were measured. Weekly serum CIT concentrations were obtained from 10 days prior until 30 days after HCT. RESULTS: Mean baseline CIT concentration was 22.7 μmol/L (95% confidence interval [CI] 17.7-27.6) on day -10, which decreased to a nadir of 7.5 μmol/L (95% CI 3.1-18.0, P = 0.017) on day 8 following HCT before returning to baseline by day 30. After adjustment for IL-6 level (1.0% lower CIT per 10% increase in interleukin-6, P = 0.004), presence of acute GVHD (27% lower CIT, P = 0.025), and oral energy intake (2.1% lower CIT per 10% decrease in energy intake, P = 0.018), the nadir shifted to day 10, when mean CIT concentration was lower in patients with severe oral mucositis (6.7 μmol/L, 95% CI 3.4-13.1) than in those without severe mucositis (11.9 μmol/L, 95% CI 5.8-24.4, P = 0.003). Change in CIT was not correlated with stool volume, C-reactive protein, tumor necrosis factor-α, leptin, or ghrelin. CONCLUSIONS: In children undergoing HCT, serum CIT correlates with measures of gastrointestinal function (oral mucositis severity, dietary intake, acute GVHD) and may reflect mucosal injury to the gastrointestinal tract.
OBJECTIVES: We sought to determine whether serum citrulline (CIT), an amino acid produced by small bowel enterocytes, was associated with clinical and biochemical markers of gastrointestinal function in children undergoing hematopoietic cell transplantation (HCT). METHODS: We conducted a multicenter, prospective cohort study of 26 children to define time-related changes in serum CIT during the course of HCT. Markers of gastrointestinal function including oral energy intake, emesis, stool volume, presence of graft-versus-host disease (GVHD), oral mucositis severity, and cytokine and neurohormone levels were measured. Weekly serum CIT concentrations were obtained from 10 days prior until 30 days after HCT. RESULTS: Mean baseline CIT concentration was 22.7 μmol/L (95% confidence interval [CI] 17.7-27.6) on day -10, which decreased to a nadir of 7.5 μmol/L (95% CI 3.1-18.0, P = 0.017) on day 8 following HCT before returning to baseline by day 30. After adjustment for IL-6 level (1.0% lower CIT per 10% increase in interleukin-6, P = 0.004), presence of acute GVHD (27% lower CIT, P = 0.025), and oral energy intake (2.1% lower CIT per 10% decrease in energy intake, P = 0.018), the nadir shifted to day 10, when mean CIT concentration was lower in patients with severe oral mucositis (6.7 μmol/L, 95% CI 3.4-13.1) than in those without severe mucositis (11.9 μmol/L, 95% CI 5.8-24.4, P = 0.003). Change in CIT was not correlated with stool volume, C-reactive protein, tumor necrosis factor-α, leptin, or ghrelin. CONCLUSIONS: In children undergoing HCT, serum CIT correlates with measures of gastrointestinal function (oral mucositis severity, dietary intake, acute GVHD) and may reflect mucosal injury to the gastrointestinal tract.
Authors: Ludy C H W Lutgens; Nicole M A Blijlevens; Nicolaas E P Deutz; J Peter Donnelly; Philippe Lambin; Ben E de Pauw Journal: Cancer Date: 2005-01-01 Impact factor: 6.860
Authors: Tyler Burpee; Paul Mitchell; Douglas Fishman; Shabana Islam; Elizabeta Nemeth; Mark Westerman; Marianne Wessling-Resnick; Richard J Grand Journal: Inflamm Bowel Dis Date: 2011-02 Impact factor: 5.325
Authors: K Ryan Wessells; Sonja Y Hess; Noel Rouamba; Zinewendé P Ouédraogo; Mark Kellogg; Rie Goto; Christopher Duggan; Jean-Bosco Ouédraogo; Kenneth H Brown Journal: J Pediatr Gastroenterol Nutr Date: 2013-09 Impact factor: 2.839
Authors: Michel J van Vliet; Wim J E Tissing; Edmond H H M Rings; Harma A Koetse; Frans Stellaard; Willem A Kamps; Eveline S J M de Bont Journal: Pediatr Blood Cancer Date: 2009-12-15 Impact factor: 3.167
Authors: Pascal Crenn; Pierre De Truchis; Nathalie Neveux; Tatiana Galpérine; Luc Cynober; Jean Claude Melchior Journal: Am J Clin Nutr Date: 2009-07-08 Impact factor: 7.045
Authors: Richard M Logan; Andrea M Stringer; Joanne M Bowen; Ann S-J Yeoh; Rachel J Gibson; Stephen T Sonis; Dorothy M K Keefe Journal: Cancer Treat Rev Date: 2007-05-15 Impact factor: 12.111
Authors: Armin Rashidi; Ryan Shanley; Shernan G Holtan; Margaret L MacMillan; Bruce R Blazar; Alexander Khoruts; Daniel J Weisdorf Journal: Biol Blood Marrow Transplant Date: 2018-07-07 Impact factor: 5.742
Authors: Anders B Nexoe; Andreas A Pedersen; Sebastian von Huth; Grith L Sorensen; Uffe Holmskov; Ping-Ping Jiang; Sönke Detlefsen; Steffen Husby; Mathias Rathe Journal: Sci Rep Date: 2021-07-19 Impact factor: 4.379
Authors: Anna Cäcilia Ingham; Katrine Kielsen; Malene Skovsted Cilieborg; Ole Lund; Susan Holmes; Frank M Aarestrup; Klaus Gottlob Müller; Sünje Johanna Pamp Journal: Microbiome Date: 2019-09-13 Impact factor: 14.650